Deals & Corporate Governance

  • February 06, 2026

    HHS Refers Hims & Hers To DOJ Amid Compound Drug Fight

    U.S. Department of Health and Human Services general counsel Mike Stuart announced Friday that his office referred Hims & Hers Health Inc. to the U.S. Department of Justice for investigation, a day after Novo Nordisk A/S threatened litigation over what it called the telehealth company's "knockoff" version of its popular weight loss drug Wegovy.

  • February 06, 2026

    Colo. Nonprofit Drops Suit Over Medicaid Therapy Cuts

    A Colorado healthcare nonprofit Thursday voluntarily dismissed its complaint seeking to reverse an allegedly unlawful executive order signed by Gov. Jared Polis that cut state Medicaid spending to pediatric behavioral therapy and autism therapy services. 

  • February 06, 2026

    SEC Alleges Pharma Co. Misled Investors About Cancer Drug

    The U.S. Securities and Exchange Commission is suing a Kentucky pharmaceutical company for securities fraud based on claims that the company raised $4.1 million by lying to investors about the status of its cancer treatment drug.

  • February 06, 2026

    NJ Watchdog Must Give Up Files In Hospital Row

    A New Jersey federal judge has refused to disturb a magistrate judge's decision compelling a state watchdog to turn over documents from its inquiry into CarePoint Health Systems Inc., rejecting the agency's bid to shield its files with grand-jury-like secrecy and reaffirming that federal privilege law governs discovery disputes in federal court.

  • February 06, 2026

    2nd Circ. Affirms Nix Of NY Anesthesiologists' Antitrust Suit

    A New York anesthesiology practice didn't sustain an antitrust injury when a UnitedHealthcare unit used its market power to cut reimbursement rates, a Second Circuit panel affirmed Friday, finding that the change in rates was a natural consequence of the health insurance system and doesn't equate to anticompetitive harm. 

  • February 05, 2026

    Novo Threatens Hims & Hers With Suit Over GLP-1 'Knockoff'

    Novo Nordisk said in a Thursday announcement it plans to take legal action against Hims & Hers Health Inc. after the telehealth company revealed a "knockoff" version of Novo's popular weight loss drug Wegovy earlier in the day. 

  • February 05, 2026

    Covington, Davis Polk Lead Eikon's Upsized $381M IPO

    Oncology-focused biopharmaceutical company Eikon Therapeutics began trading publicly Thursday after raising $381 million in its upsized initial public offering.

  • February 04, 2026

    Hartford HealthCare Must Provide Docs On $86M Takeovers

    Hartford HealthCare Corp. must hand over internal documents detailing its $86.1 million acquisitions of two hospitals from bankrupt Prospect Medical to a group of plaintiffs who accuse the health system of trying to create a monopoly for inpatient hospital services, a Connecticut state court judge has ruled.

  • February 04, 2026

    Ga. Justices Uphold $8.3M Verdict In MedMal Case

    The Georgia Supreme Court said it won't disturb a $6.5 million verdict or an additional $1.8 million attorney fee award in a suit over a botched knee surgery, with one justice clarifying what courts can do regarding jury instructions in medical malpractice cases.

  • February 04, 2026

    2nd Circ. Backs Block On Hundreds Of Geico Collection Cases

    The Second Circuit found no error in a preliminary injunction pausing over 600 collection actions filed against Geico by a doctor and medical practice accused by the insurer of a scheme to exploit New York's no-fault automobile insurance laws.

  • February 03, 2026

    This Week's Healthcare Earnings: Novo, Elevance And More

    More than half a dozen healthcare companies posted earnings this week, including big names like Pfizer, Elevance and Roche. Here's what you need to know from earnings this week.

  • February 03, 2026

    Biopharma Co.'s Down-Round IPO May Signal More To Come

    Biotech Eikon Therapeutics is preparing for a down-round IPO experts say may serve as a bellwether for how certain life sciences companies get valued in public markets.

  • February 03, 2026

    2nd Circ. Skeptical Anesthesia Group Suffered Antitrust Harm

    A Second Circuit panel seemed poised Tuesday to find that an anesthesiology practice didn't suffer an antitrust injury in its claim that a United Healthcare unit used its market power in New York to cut reimbursement rates.

  • January 30, 2026

    SelectQuote Execs Face Investor Suit Over Kickback Probe

    Executives and directors of insurance comparison platform SelectQuote were hit with a shareholder's derivative suit accusing them of concealing a kickback scheme currently subject of a False Claims Act suit by the U.S. Department of Justice.

  • January 28, 2026

    Biogen Can't Escape Amended Antitrust Suit Over MS Drug

    Biogen Inc. must face health plans' claims that it bribed pharmacy benefit managers to stifle generics competition for its multiple sclerosis drug Tecfidera, after an Illinois federal judge found Wednesday that the plans' latest amended complaint in their consolidated antitrust litigation corrects her prior concerns with the pleadings.

  • January 28, 2026

    Fla. Court Undoes Class Cert. Of Medicare Cos. In USAA Suit

    A Florida state appeals court on Wednesday reversed class certification for a group of Medicare-contracted businesses suing USAA Casualty Insurance Co. over allegations the insurer sidestepped its obligation to pay automobile injury claims and passed them on to so-called secondary payers. 

  • January 27, 2026

    This Week's Healthcare Earnings: UnitedHealth, HCA, J&J

    It was a week of good news and bad news for the healthcare industry. Earnings season kicked off when three companies posted financials for the final three months of last year, and results were mixed. Here's what you need to know about the developments.

  • January 27, 2026

    Biotech Fundraising A Good Sign For Public Markets

    At the start of what many healthcare attorneys hope will be a busy year, public biotechs are raising cash, signaling a thawing public market and potentially fertile ground for IPOs.

  • January 26, 2026

    Healthcare Group Of The Year: Holland & Knight

    Holland & Knight LLP attorneys advised AdventHealth on its multimillion-dollar outpatient acquisitions, Evernorth Health Services' $3.5 billion investment in Shields Health Solutions and Palomar Health on its strategic partnership with the University of California San Diego, earning it a spot among the 2025 Law360 Healthcare Groups of the Year.

  • January 23, 2026

    DC Circ. Revives Terrorism Liability Suit Against Pharma Cos.

    A D.C. Circuit panel revived a lawsuit Friday accusing pharmaceutical companies of aiding a Hezbollah-linked militia's terrorism in Iraq, saying the victims behind the case have adequately alleged that the companies' participation was conscious and voluntary. 

  • January 23, 2026

    Heart Valve Deal Was Blocked Over Innovation Concerns

    The D.C. federal court ruling earlier this month that upended a deal for Edwards Lifesciences Corp. to purchase JenaValve Technology Inc. was based on concerns that the deal would reduce innovation by eliminating competition for a heart valve treatment that's still being developed, according to a ruling unsealed on Friday by the judge who issued it.

  • January 21, 2026

    Health Tech SPAC Execs Ink $10M Investor Settlement

    Former executives of a health technology company that went public via merger with a blank check company have reached a $10 million deal to settle claims they wiped out investors with a bankruptcy filing after the company's product development projections derailed.

  • January 20, 2026

    Justices To Clarify What's Fair Game With 'Skinny Labels'

    A new U.S. Supreme Court patent case that will require the justices to spell out what generic-drug makers can say when marketing drugs with so-called skinny labels will shape whether and how those companies use the tactic of carving out patented uses from labels, attorneys say.

  • January 20, 2026

    What JPM Tells Us About Healthcare Deals In 2026

    Coming out of one of the bellwether events for the healthcare industry, attorneys in the space are feeling pretty good about 2026.

  • January 20, 2026

    Law360 Names Firms Of The Year

    Eight law firms have earned spots as Law360's Firms of the Year, with 48 Practice Group of the Year awards among them, achieving milestones such as high-profile litigation wins at the U.S. Supreme Court and 11-figure merger deals.

Expert Analysis

  • PE-Healthcare Mergers Should Prepare For Challenges

    Author Photo

    State and federal regulators are increasingly imposing new requirements on healthcare transactions involving private equity partners, with mergers that would have drawn little scrutiny a few years ago now requiring a multijurisdictional risk analysis during the deal formation process, say attorneys at Stinson.

  • Behind Indiana's Broad New Healthcare Transactions Law

    Author Photo

    The high materiality threshold in Indiana's recently passed healthcare transaction law, coupled with the inclusion of private equity in its definition of healthcare entities, makes it one of the broadest state review regulations to date, say attorneys at DLA Piper.

  • Highlights From The 2024 ABA Antitrust Spring Meeting

    Author Photo

    U.S. merger enforcement and cartels figured heavily in this year's American Bar Association spring antitrust meeting, where one key takeaway included news that the Federal Trade Commission's anticipated changes to the Hart-Scott-Rodino form may be less dramatic than many originally feared, say attorneys at Freshfields.

  • The Merger Cases That Will Matter At ABA Antitrust Meeting

    Author Photo

    While the American Bar Association's Antitrust Spring Meeting this week will cover all types of competition law issues in the U.S. and abroad, expect the federal agencies' recent track record in merger enforcement to be a key area of focus on the official panels and in cocktail party chatter, say attorneys at Freshfields.

  • Planning For Healthcare-Private Equity Antitrust Enforcement

    Author Photo

    U.S. antitrust agency developments could mean potential enforcement actions on healthcare-related acquisitions by private equity funds are on the way, and entities operating in this space should follow a series of practice tips, including early assessment of antitrust risks on both the state and federal level, say Ryan Quillian and John Kendrick at Covington.

  • Why Oncology Deal Making Continues To Fuel Biotech M&A

    Author Photo

    The biotech sector's potential for advancements in cancer care continues to attract deal-maker interest, and the keys to successful mergers and acquisitions include the ability to integrate innovative therapies, leverage technological advancements and respond to the dynamic needs of patients, say Bryan Luchs and Mike Weir at White & Case.

  • Tips For Healthcare M&A Amid Heightened Antitrust Scrutiny

    Author Photo

    As the Biden administration maintains its aggressive approach to antitrust merger enforcement, prudent healthcare M&A counsel will consider practical advice when contemplating their next transaction, including carefully selecting a merger partner and preparing for a potentially long waiting period prior to closing, say attorneys at Davis Wright.

  • Spartan Arbitration Tactics Against Well-Funded Opponents

    Author Photo

    Like the ancient Spartans who held off a numerically superior Persian army at the Battle of Thermopylae, trial attorneys and clients faced with arbitration against an opponent with a bigger war chest can take a strategic approach to create a pass to victory, say Kostas Katsiris and Benjamin Argyle at Venable.

  • 5 Trends To Watch As Value-Based Healthcare Gains Steam

    Author Photo

    Value-based care has grown and evolved as healthcare providers, payors and policymakers seek to improve patient results while containing costs, and this shift in the industry is expected to accelerate in the near future, say attorneys at Holland & Knight.

  • What's At Play In Rising Lanham Act Cases At The ITC

    Author Photo

    Amid an uptick in Lanham Act claims involving false advertising related to medical devices at the U.S. International Trade Commission, Brian Busey and Maryrose McLaughlin at MoFo discuss recent ITC complaints from Eli Lilly and R.J. Reynolds, Lanham Act claim limits under the Federal Food, Drug, and Cosmetic Act, and the issues practitioners face in this realm.

  • What Workplace Violence Law Means For Texas Healthcare

    Author Photo

    While no federal laws address violence against healthcare workers, Texas has recently enacted statutory protections that take effect later this year — so facilities in the state should understand their new obligations under the law, and employers in other states would be wise to take notice as well, say attorneys at Bradley Arant.

  • 5 Models For Structuring Health Provider-Payor Partnerships

    Author Photo

    With recent data showing that the U.S. continues to spend more and get less for healthcare services compared to other industrialized nations, providers and payors should consider a variety of partnership structures that can help achieve the so-called triple aim of improving the health of individuals and populations while reducing per capita costs, says John Howard at Thompson Coburn.

  • What FTC's 'Killer Acquisition' Theory Means For Pharma Cos.

    Author Photo

    The Federal Trade Commission's recent lawsuit to block Sanofi's acquisition of a pharmaceutical treatment developed by Maze Therapeutics builds on previous enforcement actions and could indicate the agency's growing willingness to use its so-called killer acquisition theory against perceived attempts to eliminate nascent competition, say attorneys at Morgan Lewis.